Table 1 Patient clinical, demographic and neuropsychological data

Age/sex	Handedness	Epilepsy onset (y)	Seizure types and frequency (per month)	Postop outcome (ILAE class)	MRI and pathological diagnosis	Clinical and EEG	Preop naming (centile)	Postop naming (centile)	Naming change	AEDs (mg/day)	LD
37/M	Left	1	SPS 12 CPS 4	2	Left HS	Left TLE	19 (50^th)	16 (25^th)	−3	VPA 800 CBZ 800 LVT 2000	Left
33/M	Right	1	SPS 4 CPS 4	1	Left HS	Left TLE	13 (5^th)	15 (10^th)	2	PMD 500 CBZ 1200 CLB 10 TPR 175 LVT 4000	Left
25/F	Right	17	CPS 8 SGTC 0.5	1	Left HS	Left TLE	7 (<1^st)	5 (<1^st)	−2	TPR 150 LTG 300	Left
28/M	Right	3	CPS 1	1	Left HS	Left TLE	4 (<1^st)	7 (<1^st)	3	LVT 3000 LTG 600	Left
31/M	Right	10	CPS 50 SGTC 3	1	Left MTL DNET	Left TLE	14 (10^th)	10 (<1^st)	−4	CBZ 1200 CLN 1.5 LTG 100	Left
37/F	Right	1	SPS 12 CPS 8 SGTC 1	3	Left HS, left fusiform gyrus ganglioglioma	Left TLE	10 (<1^st)	13 (5^th)	3	CBZ 1000 CLB 10	Left
36/M	Left	15	SPS 6 CPS 6 SGTC 3	1	Right MTL glioma	Right TLE	17 (25^th)	2 (<1^st)	−15	CBZ 1600 CLB 20 LTG 400	Right

AED, antiepileptic drug; CBZ, carbamazepine; CLB, clobazam; CLN, clonazepam; CPS, complex partial seizure; DNET, dysembryoplastic neuroepithelial tumour; HS, hippocampal sclerosis; ILAE, International League Against Epilepsy; LD, language dominance; LTG, lamotrigine; LVT, levetiracetam; MTL, medial temporal lobe; NA, not applicable; PMD, primidone; SGTC, secondary generalised tonic–clonic seizure; SPS, simple partial seizure; TLE, temporal lobe epilepsy; TPR, topiramate; VPA, sodium valproate.